Introduction
Although platelets have been established to be of primary importance in arterial thrombosis (Genton, Weily and Steele, 1973) , the change which initiates arterial thrombosis probably occurs in the wall of the blood vessel rather than in the platelet. Platelet interaction with damaged vessel walls, altered blood flow, and platelet aggregation, are contributory events to arterial thrombosis. Model systems in vivo and in vitro representing these events have been developed, and a number of naturally occurring prostaglandins (PGs) have been examined in each system to determine the possible role of PGs in thrombosis. The PGs examined included the relatively stable E2, F2., D2 and E1 plus some of their pulmonary metabolites. Also the labile PGG2 which is the precursor of the '2 series PGs', thromboxanes and prostacyclin have been examined.
Methods

Platelet aggregation
This was quantitated as an increase in light transmission in stirred platelet-rich plasma (PRP) (Born and Cross, 1963) . The effect of PG on ADPinduced human platelet aggregation was performed as described by Westwick (1976) . Briefly, following a 2-min pre-incubation period of the PRP at 37'C, 50 ,ul of vehicle or prostaglandin (final concentration 5 x 10-9 to 5 x 10-5 mol/l) was added followed 3 min later by ADP (1-3 x 10-6 mol/l). Each concentration of PG was tested [3] [4] [5] 
Blood flow
The hamster cheek pouch preparation (HCP) as described by Lewis and Westwick (1975) was modified so that arterioles of 25-45 ,am resting diameter could be monitored for up to 3 hr. Constriction and dilatation of the arterioles were measured by a photometric technique (Hutchings et al., 1976) .
The relatively stable prostaglandins, E2, F2., E1
and their pulmonary metabolites plus PGD2 were infused for 5-min intervals into the Krebs solution superfusing the cheek pouch in concentrations ranging from 0-6 to 400 ng/ml/min (Lewis and Westwick, 1976) . Each concentration was assayed in a minimum of 4 hamsters. The unstable PGG2
(half-life in saline at 38°C is 6 min) was stored in dry acetone at -20°C at 500 ,ug/ml. When required the stock solution was diluted either in saline or acetone at 0°C and applied immediately (0 5-5 [L) into the Krebs solution adjacent to the arteriole being monitored. PGG, was examined in doses of 5-500 ng.
Thrombus formation
Prostaglandin (G2, D2, E2 and E1) or vehicle was applied peri-vascularly to arterioles (40-70 ,um diameter) of HCP followed 30 sec later by electrical micro-damage (Westwick and Lewis, unpublished data, 1977 ) and 1 min later by perivascular applications of ADP (10-6 mol/l final concentration). Thrombus formation was quantitated by measuring the total time during which thrombi were present within a period of 10 min. Each animal was its own control and results were expressed as percentage difference (mean ± s.e. mean) from control.
Results
Platelet aggregation
The 15-keto and 13,14-dihydro-15-keto-PGE1, PGE2 and PGF2,, were inactive at concentrations below 50 tlmol/l. However, 13,14-dihydro derivatives were very active with the following IC50 (t±mol/l) values: PGE1 (0-08), 13,14-dihydro-PGE1 (0-037), PGE2 (13-0), 13,14-dihydro-PGE2 (20-0). Also PGE2 and 13,14-dihydro-PGE2 produced a significant potentiation of platelet aggregation at 0'08-0-26
[mol/l (Fig. 1 ).
Blood flow PGE2 was the most potent vasodilator substance examined producing a 50% increase in diameter in a concentration of 1-2 ng/ml/min. The relative potencies were as follows PGE2> 13,14-dihydro-PGE2>PGE1> 13,14 -dihydro -PGE1> bradykinin. The other pulmonary metabolites can be regarded an inactive, for example 15-keto-PGE2 is 200 times less active than the parent PGE2. PGD2 (>20 ng) produced a small vasoconstriction.
On arterioles which had a high resting tone, PGG2 in low concentrations (5 ng) induced a vasodilatation only. Higher concentrations (25-100 ng) produced a short-lasting vasoconstriction (30 sec) followed by a protracted phase of vasodilatation (60-100% with 25-100 ng PGG2). On arterioles having a low vascular tone, a short-lasting vasoconstriction was induced, e.g. 25 ng produced 93 + 2% constriction (mean ± s.e. mean, n=6). Repeated doses of PGG2 rapidly induced tachyphylaxis (Lewis, Westwick and Williams, 1977 
Discussion
These results demonstrate that prostaglandins can exhibit both pro-and anti-thrombotic activity in model systems of thrombosis (Table 1) . The E series PGs and the 13,14-dihydro-metabolites are very potent vasodilators in a number of species (for review see Messina, Weiner and Kaley, 1974) . However, PGE1 and PGE2 (Bergstrom, Carlsson and Weeks, 1968) plus their 13,14-dihydro-metabolites have dramatically opposing effects on platelet aggregation (Westwick, 1976) . PGE1 is a very good inhibitor of thrombus formation in vivo in the hamster, as was also shown in the rabbit pial arteries by Emmons et al. (1967) . Whereas it is clear that PGE2 is pro-thrombotic, i.e. potentiates ADP-induced aggregation of human platelets and potentiates thrombus formation in HCP arterioles.
PGD2 has been shown to be a potent inhibitor of human platelet aggregation but ineffective on rat platelets (Smith et al., 1974) . In these experiments, PGD2 did not inhibit thrombus formation in HCP arterioles, and it was a weak vaso-constrictor agent.
As might be expected from its key position in the metabolism of arachidonic acid (Johnson et al., 1976) , the endoperoxide PGG2 exhibited apparently opposing effects depending upon which model It appears likely that PGG2 has been converted in vivo by HCP vascular tissue to prostacyclin, which produced the inhibition of thrombus formation. Prostacyclin can be generated by vessel wall microsomes in vitro and has been shown to inhibit platelet aggregation in vitro .
From these experiments the metabolic fate of any PGG2 produced in vivo is of utmost importance. For example, if PGG2 is converted to PGE2 then a pro-thrombotic situation will prevail, but if PGG2 is converted to PGD2 or prostacyclin, then an antithrombotic situation will exist. However, if PGG2 comes in contact with platelets only, then a prothrombotic situation will arise owing either to the direct effect of PGG2 or to thromboxane generation .
Thus blood flow and thrombosis can be locally modulated by the various types of prostaglandins produced by blood and vascular tissue.
